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Abstract
Regeneration of load-bearing segmental bone defects is a 
major challenge in trauma and orthopaedic surgery. The 
ideal bone graft substitute is a biomaterial that provides 
immediate mechanical stability, while stimulating bone 
regeneration to completely bridge defects over a short 
period. Therefore, selective laser melted porous titanium, 
designed and fine-tuned to tolerate full load-bearing, 
was filled with a physiologically concentrated fibrin gel 
loaded with bone morphogenetic protein-2 (BMP-2). This 
biomaterial was used to graft critical-sized segmental 
femoral bone defects in rats. As a control, porous titanium 
implants were either left empty or filled with a fibrin 
gels without BMP-2. We evaluated bone regeneration, 
bone quality and mechanical strength of grafted femora 
using in vivo and ex vivo µCT scanning, histology, and 
torsion testing. This biomaterial completely regenerated 
and bridged the critical-sized bone defects within eight 
weeks. After twelve weeks, femora were anatomically 
re-shaped and revealed open medullary cavities. More 
importantly, new bone was formed throughout the entire 
porous titanium implants and grafted femora regained more 
than their innate mechanical stability: torsional strength 
exceeded twice their original strength. In conclusion, 
combining porous titanium implants with a physiologically 
concentrated fibrin gels loaded with BMP-2 improved 
bone regeneration in load-bearing segmental defects. This 
material combination now awaits its evaluation in larger 
animal models to show its suitability for grafting load-
bearing defects in trauma and orthopaedic surgery.
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Introduction
A major challenge in trauma and orthopaedic surgery is 
to successfully repair load-bearing segmental bone defects 
(Einhorn, 1995). This often requires the use of bone grafts 
or bone graft substitutes to improve bone regeneration by 
providing an osteoconductive matrix, offering mechanical 
support, or an osteoinductive and/or osteogenic stimulus 
(Giannoudis et al., 2011). The golden standard bone graft 
is still autologous bone (Pape et al., 2010), but the amount 
of bone that can be harvested is limited and associated with 
complications in 10-40 % (Banwart et al., 1995). These 
disadvantages motivate the development of biomaterials 
that can be used as bone graft substitutes (Langer and 
Vacanti, 1993).
 A biomaterial that has the potential to become a 
bone graft substitute is porous titanium (Alvarez and 
Nakajima, 2009; Murr et al., 2010; Ryan et al., 2006). 
Nowadays, porous titanium can be manufactured using 
additive manufacturing techniques such as selective laser 
melting (SLM) (Hollander et al., 2006). This enables 
the design of porous titanium so that its structure and 
mechanical strength remains suitable to function as a 
load-bearing osteoconductive matrix in segmental bone 
defects (Van der Stok et al., 2013a). Osseointegration of 
titanium is optimised through relatively simple chemical 
and heat treatments that alter the surface chemistry and 
(nano-) topography (Amin Yavari et al., 2014a). Thereby, 
the bioinert titanium surface changes into a bioactive 
surface that allows spontaneous apatite formation and 
stimulates proliferation and osteogenic differentiation of 
osteoprogenitor cells (Amin Yavari et al., 2014b). This 
surface-treated porous titanium forms a load-bearing 
osteoconductive matrix, but stimulating bone regeneration 
and adequate bridging of segmental bone defects may be 
further improved by addition of effective biological stimuli 
(i.e. osteoinductive cytokines) (de Wild et al., 2013; Van 
der Stok et al., 2013a).
 Bone morphogenetic proteins (BMPs) such as BMP-
2 and BMP-7 play a major role in bone regeneration as 
osteoinductive cytokines (Urist, 1965). Their osteoinductive 
effects have been established in a wide range of species, 
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varying from mice and rats to humans (Murakami et al., 
2002). BMP-2 and BMP-7 have received USA Food and 
Drugs Administration (FDA) approval for use in trauma 
and orthopaedic surgery (Senta et al., 2009), but their 
clinical success is limited (Khan and Lane, 2004). This 
might be because a supra-physiological dosage of BMP 
needs to be loaded onto an absorbable collagen sponge to 
reach an effect (Termaat et al., 2005). This high dose has 
been associated with adverse effects including bone tissue 
overgrowth, ectopic bone formation, inflammation, and 
even carcinogenicity (Carragee et al., 2011; Woo, 2013). 
To overcome this, numerous slow-release systems have 
been developed. Interestingly, these slow-release systems, 
allowing for controlled release of BMP-2 during several 
weeks, do not resemble the natural bone regeneration 
process in which BMP-2 is mainly released during the first 
few days (Cho et al., 2002; Gerstenfeld et al., 2003).
 Bone regeneration starts with the formation of a fibrin 
clot, often referred to as the fracture haematoma. This fibrin 
clot forms the natural binding reservoir for osteoinductive 
cytokines such as BMP-2 (Gerstenfeld et al., 2003; 
Martino et al., 2013) and is formed through conversion 
of fibrinogen by thrombin. Fibrinogen is synthesised in 
its high molecular weight form, but occurs as a mixture 
together with partially degraded low molecular weight 
forms in circulation (Kaijzel et al., 2006). Fibrin gels, made 
from physiological fibrinogen concentrations (2-4 mg/L), 
are highly permeable to cells (Kaijzel et al., 2006). 
However, at these physiological concentrations, fibrin 
gels are soft and therefore not suitable for most clinical 
applications. Consequently, commercially available fibrin 
sealants contain very high fibrinogen concentrations (50-
100 mg/L) (Janmey et al., 2009) at the cost of seriously 
compromising the favourable cellular permeability of these 
gels. When incorporated into porous titanium, the use of 
physiologically concentrated fibrin gels becomes feasible 
as the metal frame ensures mechanical support, then. The 
surface-treated porous titanium implants may even improve 
the network organisation of fibrin fibres (Milleret et al., 
2011).
 The aim of the current study was to develop a 
biomaterial capable of improving bone regeneration of 
segmental bone defects: osteoconductive load-bearing 
porous titanium filled with physiologically concentrated 
fibrin gels releasing BMP-2. For this novel combination, 
the BMP-2 releasing fibrin gel was prepared from purified 
high molecular weight (HMW) fibrinogen, since HMW 
fibrinogen increases angiogenesis in vitro and in vivo. 
(Kaijzel et al., 2006). To determine whether the angiogenic 
HMW fibrin gel alone is capable of increasing bone 
regeneration, porous titanium implants were also filled 
with HMW fibrin gels without BMP-2 and compared to 
unfractionated (UNF) fibrin gels. Porous titanium implants 
incorporated with the three above described fibrin gels were 
compared to empty porous titanium implants in a critical-
sized load-bearing segmental femur defect in rats using in 
vivo (4, 8 and 12 weeks) and ex vivo (after 12 weeks) µCT 
scans, histology, and biomechanical torsion tests.
Materials and Methods
Porous titanium implants
Porous titanium implants were produced from Ti6Al4V 
ELI powder (ASTM B348, grade 23) using selective laser 
melting (SLM, Layerwise N.V., Leuven, Belgium). The 
implants were a copy of the replaced femoral bone segment 
and had a height of 6 mm, a maximum outer diameter of 
5 mm and a minimal inner diameter of 1.3 mm (leaving an 
open medullary canal). The porous architecture was based 
on a dodecahedron unit cell with a strut width of 120 µm 
and an average pore size of 500 µm, to result in 55 mm3 
porous volume. All implants underwent a post-production 
alkali-acid-heat treatment consisting of (1) immersion 
in a 5 M aqueous NaOH solution at 60 °C for 24 h; (2) 
immersion in water at 40 °C for 24 h; (3) immersion in 
0.5 mM HCl at 40 °C for 24 h; (4) heating to 600 °C at 
a rate of 5 °C/min in an electric furnace at ambient air 
pressure, keeping the temperature at 600 °C for 1 h, and 
subsequent natural cooling (Amin Yavari et al., 2014b). 
Reproducibility of porous implant architecture (e.g., pore 
size, titanium strut thickness and porosity) was verified 
by µCT (SkyScan 1076; Bruker micro-CT N.V., Kontich, 
Belgium).
Fibrin gel preparation
Fibrin gel preparation was done as previously described 
(Holm et al., 1985; Kaijzel et al., 2006). Briefly, 
plasminogen-rich unfractionated human fibrinogen 
(Chromogenix, Mölndal, Sweden) was dissolved in Tris 
buffer (10 mM Tris/HCl, pH 7.4) to a concentration of 
5 mg/mL. Saturated (NH4)2SO4 was slowly added to a final 
concentration of 19 % (v/v) and the solution was mixed 
for 30 min at room temperature prior to centrifugation 
for 10 min at 2,000 × g. Repetition of this precipitation 
step resulted in a HMW fibrinogen pellet (~ 99 % purity), 
which were dissolved in 5 mL of saline (0.9 % NaCl) and 
then dialysed against M199 culture medium, as was the 
UNF fibrinogen. Purity was determined using standard 
non-reducing sodium dodecylsulphate polyacrylamide gel 
electrophoresis and concentrations were calculated using 
the molar extinction coefficient of fibrinogen (E1 % 280 nm 
for fibrinogen is 15.8). The preparations were stored in 
single-use aliquots at -80 °C until further use.
 In a custom-made mould, the porous titanium implants 
were filled with 55 µL of either HMW fibrinogen (2 mg/
mL, HMW-Fb) or UNF fibrinogen (2 mg/mL, UNF-Fb) 
which were clotted with 0.5 IU/mL of thrombin (Global 
Siemens Healthcare, Erlangen, Germany) dissolved 
in a 4.5 mM calcium chloride buffer (Baxter, Utrecht, 
Netherlands) in a 8.5:1 ratio. HMW fibrin gels with BMP-
2 (HWM-BMP-Fb) were made by adding 3 μg BMP-2 
(Shanghai Rebone Biomaterials Co., China) in 1 mM saline 
solution to the HWM fibrinogen solution before clotting. 
Prior to implantation, after clotting the fibrin-filled implants 
were wrapped in Parafilm® and incubated for 15-18 h at 
6 °C to allow completion of fibrin gelling.
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Scanning electron microscopy (SEM)
To determine filling efficacy and to characterise the 
structure of the fibrin networks polymerised from HMW 
and UNF fibrinogen, SEM was used as follows: implants 
were filled with fibrin gels and fixed in 3 % glutaraldehyde 
for 24 h and rinsed with sodium phosphate buffer (0.1 M, 
pH 7.2-7.4; Merck). Samples were then consecutively 
dehydrated in ascending alcohol concentrations (30, 50, 
70 and 90 % v/v) with three final incubations in 100 % 
ethanol for 10 min each. Probes were critical-point-dried 
in liquid CO2 and then sputtered with a 30 nm gold layer. 
Samples were analysed in FEI/Philips XL 30 FEG ESEM 
(Philips) in a high vacuum environment.
Load-bearing segmental bone defects
Critical-sized segmental bone defects were made in the 
femora of 40 male 16-weeks-old Wistar rats (446 ± 32 
g). Rats were divided into four experimental groups 
receiving porous titanium implants filled with HMW-
BMP-Fb, HMW-Fb and UNF-Fb or were left empty 
(empty). The Animal Ethics Committee of the Erasmus 
University approved the study and Dutch guidelines for 
care and use of laboratory animals were followed. Before 
surgery, rats received subcutaneous injections of antibiotics 
(enrofloxacin, 5 mg/kg body weight) and pain medication 
(buprenorphine, 0.05 mg/kg body weight). Surgery was 
performed aseptically under general anaesthesia (1-3.5 % 
isoflurane). The right femur was exposed through a lateral 
skin incision and separation of underlying fascia. Using 
three proximal and three distal screws, a 23 × 3 × 2 mm 
polyether ether ketone (PEEK) plate (RISystem, Davos 
Platz, Switzerland) was fixed to the femur anterolateral 
plane. Periosteum was removed over 8 mm of the mid-
diaphyseal region before a 6 mm cortical bone segment 
was removed with a wire saw and a tailor-made saw 
guide. Subsequently, a porous titanium implant was 
implanted press-fit into the defect. Finally, fascia and skin 
were sutured. Subcutaneous injection of pain medication 
(buprenorphine, 0.05 mg/kg body weight) was given twice 
a day for the following three days. Rats were sacrificed after 
twelve weeks with an overdose of pentobarbital (200 mg/
kg body weight).
µCT evaluation
Bone regeneration was measured by in vivo µCT scans 
(SkyScan 1076; Bruker micro-CT N.V., Kontich, Belgium) 
at four, eight and twelve weeks, and by ex vivo µCT scans 
on isolated grafted femora at the end of the experiment. 
Rats were kept under general anaesthesia (1-3.5 % 
isoflurane) during in vivo µCT scans at 35 µm resolution 
(95 kV, 105 µA current, 1.0 mm Al/0.25 mm Cu filter, 
and 0.75° rotation step, 14 min scan). Ex vivo µCT scans 
were acquired at 18 µm resolution (95 kV, 100 µA current, 
1.0 mm Al/0.25 mm Cu filter, and 0.5° rotation step). 
µCT scan images were reconstructed using volumetric 
reconstruction software NRecon version 1.6.6 (Bruker 
micro-CT N.V., Kontich, Belgium).
 Bone regeneration was expressed as bone volume (BV), 
which was measured at four specific regions: 1) total BV: 
the total volume of bone formed within the 6 mm defect; 
2) porous BV: the bone formed inside the porous space of 
the titanium implants; 3) outer BV: the bone formed outside 
the porous titanium implants; and 4) inner BV: the bone 
formed in the medullary canal of the implants. BV values 
were measured using CTAnalyser version 1.13 (Bruker 
micro-CT N.V., Kontich, Belgium). First the specific region 
was selected, then the titanium and its border artefacts 
was excluded from images using a global threshold with a 
value between titanium and bone and removal of an extra 
35 µm border (size of one pixel) surrounding the titanium. 
Subsequently the bone was extracted by using a second 
global threshold that differentiated between bone and soft 
tissue. The global threshold values were chosen on visual 
inspection and were kept constant for all scans. Bone 
bridging was assessed on ex vivo scans with DataViewer 
1.4 (Bruker micro-CT N.V., Kontich, Belgium). Complete 
bone bridging was defined as bridging of three or more 
cortices counted on ex vivo scans in the coronal and sagittal 
plane. Bone bridging was quantified by measuring the 
shortest remaining gap size between bone formed at the 
proximal and distal site of the 6 mm bone defect.
Histological evaluation
Histology was performed on two femora per group that 
represented the mean of the whole group. To select these 
two femora, all ten grafted femora were sorted according 
to their total BV after twelve weeks and the two femora 
closest to the averaged value were chosen. Harvested 
femora were fixed in 10 % neutral buffered formalin 
solution for two days, dehydrated in ascending alcohol 
concentrations (70 to 100 % v/v), and finally embedded 
in methyl methacrylate (MMA). Sections of ~ 20 µm were 
obtained using a diamond saw (Leica SP1600, Rijswijk, 
The Netherlands) and stained with basic fuchsin 0.3 % 
(w/v) solution and methylene blue 1 % (w/v) solution to 
stain bone purple and fibrous tissue blue, respectively. 
Serial sections were then screened for bone formation, 
bone-implant contact and bone bridging.
Biomechanical tests
Mechanical strengths of grafted femora were measured 
by a torsion test conducted on the remaining eight femora 
of each group. Three contralateral femora, serving as a 
reference of intact femora, were included as controls. After 
harvesting the femora, soft tissues and PEEK plates were 
carefully removed. Specimens were kept in 10 % neutral 
buffered formalin solution for two days, minimising the 
effects of formalin conservation on mechanical properties 
(Unger et al., 2010), and then transferred to phosphate 
buffered saline. Subsequently, both ends of each femur 
were embedded in a cold-cured epoxy resin (Technovit 
4071, Heraeus Kulzer, Germany). On the upper clamping 
side, a Cardan joint was used to ensure pure rotation 
without bending. The lower sides were simply fixed. Tests 
were performed until failure with a rotation rate of 0.5° s-1 
using a static mechanical testing machine that could apply 
a maximum torque of 450 N.mm (Zwick GmbH, Ulm, 
Germany). Torsional strength (maximum torque to failure, 
N.mm) was determined.
144 www.ecmjournal.org
J van der Stok et al.                                                                        Porous titanium implants for segmental bone defects
Statistics
Statistical analyses were performed using SPSS Statistics 
20.0 (SPSS, Inc.). Data are presented as means with standard 
deviations. One-way analysis of variation (ANOVA) and 
subsequent post hoc pairwise comparisons with Bonferroni 
adjustment were used to test for differences between 
the four groups. A power calculation (β-value > 0.80, 
SD ~ 25 %) was made to find a true difference in total 
BV of at least 35 %. Based on this calculation, n = 10 was 
required. A p < 0.05 was considered statistically significant.
Results
Porous titanium implants incorporated with fibrin 
gels
Porous titanium implants were produced using SLM in 
the anatomical shape of the surgically removed cortical 
bone segment (Fig. 1a). The implants had a porosity of 
85 % and a pore size ranging from 460-670 µm (Table 
1). The alkali-acid-heat treatment resulted in a titanium 
oxide layer with an irregular nano-scale features (Table 
1). Macroscopic inspection and SEM analyses verified that 
the pores of the titanium implants were completely filled 
with fibrin gel (Fig. 1a-b). The protein fibres of both fibrin 
gels attached intimately to the surface-treated titanium 
(Fig. 1c). In addition, SEM showed clear differences 
between HMW-Fb and UNF-Fb gels with respect to their 
nanofiber structures: as compared to the fibre network 
formed by unfractionated fibrinogen, resulting in a much 
denser structures with smaller average pore diameters and 
Table 1. Properties of porous titanium implants (Amin 
Yavari et al., 2014b; Van der Stok et al., 2013a).
Titanium implant
Titanium thickness 165 ± 43 µm 
Pore size 577 ± 146 µm 
(range 460-670 µm)
Porosity 85 %
Pore volume 55 mm3
Compression strength 14 MPa
Young’s modulus 0.4 GPa
Surface area / volume 0.034 µm2
Surface composition Oxygen 35 %
Titanium 60 %
Vanadium 2 %
Aluminium 3 %
Surface topography (SEM)
Fig. 1. SEM images of fibrin loaded porous titanium implants. Macroscopic overview, and enlarged details, of a fully 
fibrin-filled implant (a, b). The fibrin fibres are tightly bound to the implant surface (c). The fibre network resulting 
from unfractionated fibrinogen is rather dense with thin fibres (d). The fibrin network from HMW fibrinogen reveals a 
more-open, better-permeable, structure with slightly thicker fibres (e).
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thinner fibres (Fig. 1d), polymerisation of high molecular 
weight fibrinogen appeared to form a more open network 
with relatively thicker fibres (Fig. 1e).
Load-bearing segmental bone defects
All rats were able to tolerate weight-bearing activities 
immediately after surgery; the implantation sites healed 
without complications and all animals remained healthy 
during the follow-up.
µCT evaluation
Porous titanium implants with HMW-BMP-Fb gels 
effectively stimulated bone regeneration (Fig. 2). Within 
four weeks, bone regeneration had occurred throughout 
the entire length of the porous titanium implants and 
after eight weeks, bridging of the defect was complete. 
Only minimal bone regeneration was observed in those 
defects grafted with HMW-Fb containing porous titanium 
implants and consequently failed to bridge (Fig. 2). The 
load-bearing segmental defects grafted with HMW-BMP-
Fb containing porous titanium implants fully restored the 
original bone architecture after twelve weeks (Fig. 2 and 
3). Incorporation of HMW-Fb or UNF-Fb did not seem to 
outperform the empty porous titanium implants (Fig. 3).
 Quantitative analysis of regenerated bone, based 
on in vivo µCT scans, showed that the total BVs of the 
HMW-BMP-Fb group increased at each time point and 
reached an average of 65.1 ± 14.9 mm3 after twelve 
weeks (Fig. 4a). This was significantly higher than all the 
three control groups. Neither the total BV of the HMW-
Fb (37.7 ± 26.4 mm3) group nor that of the UNF-Fb 
(32.1 ± 13.4 mm3) group was significantly different from 
Fig. 2. Representative longitudinal µCT scans illustrating the bone regeneration process. In vivo scans of defects 
grafted with porous titanium implants incorporated with high molecular weight fibrin with BMP-2 (HMW-BMP-Fb 
group) and high molecular weight without BMP-2 (HMW-Fb group) after four (a1-2), eight (b1-2) and twelve weeks 
(c1-2) as well as ex vivo after twelve weeks (d1-2). In the HMW-BMP-Fb group, rapid bone regeneration throughout 
the complete length of the defect is already observed after four weeks (a1, arrows). Between eight and twelve weeks, 
the cortex and medullary canal (indicated by ‘m’) are restored in their original shape (b1, c1, and d1). In the HMW-
Fb group, bone regeneration is only observed at the proximal and distal side of the porous implants (a2, arrows); 
this bone is predominantly situated in the medullary canal and insufficiently bridging the defect (d2). Distally from 
the titanium implants, bone resorption is observed between eight and twelve weeks (asterisk). Bar indicates 1 mm.
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the total BV of the empty group (33.7 ± 16.8 mm3) (Fig. 
4a). Also, the porous BV and outer BV of the HMW-BMP-
Fb group were significantly higher than that of all three 
control groups (Fig. 4b-c). After twelve weeks, 51 ± 8 % 
of the available pore space of the titanium implants with 
HMW-BMP-Fb gels was filled with regenerated bone, 
twice as much as in the HMW-Fb (24 ± 18 %) and UNF-Fb 
(21 ± 5 %) group, respectively. The inner BV of the HMW-
BMP-Fb group (3.9 ± 1.6 mm3) significantly increased as 
compared to the control groups after four weeks. Contrary 
to the HMW-Fb and UNF-Fb groups, the inner BV of the 
HMW-BMP-Fb decreased over time (3.1 ± 1.3 mm3 at 8 
weeks and 2.6 ± 1.3 mm3 at 12 weeks) and even became 
significantly less than in the inner BV of the HMW-Fb 
group (Fig. 4d).
 Bone bridging, determined on ex vivo µCT scans at 
twelve weeks, was only seen in the cortical defects grafted 
with porous titanium implants filled with HMW-BMP-Fb 
gels (Fig. 5). Seven defects were completely bridged, 
and the average remaining gap size in the three defects 
that were not bridged was 0.8 ± 0.1 mm (Fig. 6a). The 
remaining gap size in the other three experimental groups 
was 1.8 ± 1.6 mm (HMW-Fb group), 1.9 ± 0.9 mm (UNF-
Fb group) and 1.8 ± 1.4 mm (empty group), respectively.
Histological evaluation
Bone quality, assessed using light microscopy, showed 
that in the HMW-BMP-Fb group bone was formed almost 
exclusively at the site of the original cortex and an intimate 
contact between the regenerated bone and the titanium 
implant was found throughout the entire length of the 
defect (Fig. 7d vs. a-c). In the HMW-Fb (Fig. 7c), UNF-
Fb (Fig. 7b) and empty groups (Fig. 7a), bone formation 
occurred predominantly at the distal and proximal sites of 
the titanium implants that were close to the adjacent cortical 
bone. This bone formation never extended throughout the 
entire length of the porous implant. The remaining gaps in 
the defects were rather filled with amorphous fibrous tissue 
(Fig. 7a, b, and c). Strikingly, in the HMW-BMP-Fb group 
an open medullary canal was observed after twelve weeks 
(Fig. 7d), whereas in all control groups bone formation was 
blocking the medullary canal (Fig. 7a-c).
Biomechanical evaluation
Femora of the HMW-BMP-Fb group reached a significantly 
higher maximum torque than the three control groups (Fig. 
6b). The specimens were more than twice as strong as 
control femora (248 %) and six femora of this HMW-
BMP-Fb group were able to resist the maximum torque 
(450 N.mm) without breaking. Femora of the HMW-Fb 
group did not differ in maximum torque from the femora 
of the UNF-Fb or empty group. The average maximum 
torques were 60 % (HMW-Fb group, 86 ± 29 N.mm), 51 % 
(UNF-Fb group, 75 ± 20 N.mm), and 53 % (empty group, 
77 ± 53 N.mm), respectively, of the average maximum 
torque measured for control femora (146 ± 19 N.mm) 
(Fig. 6b).
Discussion
An ideal biomaterial, that can be used as a bone graft 
substitute, should be able to fully regenerate and bridge 
load-bearing segmental bone defects within a short period 
of time (Langer and Vacanti, 1993). Our combination of 
surface-treated porous titanium with BMP-2 containing 
Fig. 3. Representative transversal ex vivo µCT images of grafted segmental femur defects. Titanium implants and 
fixation screws appear in black, whereas bone appears in dark grey. In the empty (a), UNF-Fb (b) and HMW-Fb (c) 
groups; bone regeneration is predominantly seen at the proximal and distal third of the porous titanium implants. 
Some new bone has formed inside the porous implants, but most of the newly formed bone is seen in the medullary 
canal. In the HMW-BMP-Fb group (d), bone regeneration extended throughout the entire porous titanium implants, 
bridging the defect. Bone formed inside the porous implant, and no bone has been formed inside the medullary canal. 
Black bar indicates 1 mm.
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Fig. 4. Longitudinal quantification of bone regeneration. In vivo µCT scans after four, eight and twelve weeks; 
total BV (a); defined as all bone formed within the 6 mm defect. Outer BV (b), defined as bone formed outside the 
titanium implants. Porous BV (c), defined as bone formed inside the porous space of the titanium implants. Inner BV 
(d), defined as bone formed in the medullary canal of the titanium implants. Values are expressed as mean and SD 
(n = 10 per group), and a one-way ANOVA test followed by a post-hoc Bonferroni correction was performed to test 
for statistical significant difference at each time point; p < 0.05 was considered as statistically significant, vertical 
bars indicate the significant differences found between the groups.
Fig. 5. Illustration of bone bridging. Representative 3D µCT images showing the average extend of bone bridging of 
the empty (a), UNF-Fb (b), HMW-Fb (c), as well as the HMW-BMP-Fb (d) group. Porous titanium implants appear 
in transparent grey, whereas bone appears in yellow/dark grey.
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Fig. 6. Bone bridging and mechanical 
strength. The remaining gap size after twelve 
weeks was used to indicate bridging success 
(a). Mechanical femoral strength after 
implantation of porous titanium implants 
measured by torsion testing (b). As a positive 
control, three control femora were included 
to provide a reference of a normal strength 
of femora during torsion testing (b, control). 
Values are expressed as mean and SD, and 
a one-way ANOVA test followed by a post-
hoc Bonferroni correction was performed 
to test for statistical significant differences 
at each time point; p < 0.05 was considered 
as statistically significant, horizontal bars 
indicate significant differences between 
groups.
Fig. 7. Histological evaluation of bone bridging. Representative transversal sections of femur defects twelve weeks 
after implantation of porous titanium implants; empty (a), or incorporated with UNF-Fb (b), HMW-Fb (c) or HMW-
BMP-Fb gels (d). Magnification reveals re-colonisation of the medulla with small round-shaped cells of a typical 
bone marrow stroma appearance. Sections are stained with basic fuchsin and methylene blue. Basic fuchsin stains 
bone purple, methylene blue stains fibrous tissue blue. Black bar indicates 1 mm.
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physiologically concentrated fibrin gels fully regenerated 
segmental bone defects in rat femora (Fig. 2 and 5) 
and fully recovered their mechanical strength (Fig. 6). 
Moreover, combining osteoconductive titanium with an 
osteoinductive BMP-2 releasing fibrin gel resulted in 
“guided” bone regeneration; i.e. new bone was formed 
throughout the porous titanium implants (Fig. 2) to 
specifically restore the cortex to its native anatomical shape 
as well as the medullary canal (Fig. 3 and 7d).
 Biomaterials used for load-bearing segmental defects 
should offer sufficient support to withstand mechanical 
loading (Giannoudis et al., 2011). A material with such 
mechanical properties is titanium, and solid titanium 
implants have been very successfully used in trauma and 
orthopaedic surgery over the past decades (Learmonth et 
al., 2007). However, the notable biomechanical mismatch 
between solid titanium implants and surrounding bone 
frequently leads to stress-shielding, subsequent bone 
resorption and implant loosening (Niinomi, 2008). 
This limitation can be overcome by using mechanically 
optimised porous titanium implants (Murr et al., 2011; 
Ryan et al., 2009), the development of which greatly 
benefited from the introduction of additive manufacturing 
techniques. Techniques such as selective laser melting 
(Hollander et al., 2006; Mullen et al., 2009; Stamp et al., 
2009), electron beam melting (EBM) (Heinl et al., 2008; 
Hrabe et al., 2011; Ponader et al., 2010) or similar additive 
manufacturing techniques (Bandyopadhyay et al., 2010; 
Bandyopadhyay et al., 2009) allow for a personalised, 
anatomical implant design and control of its structural 
and mechanical properties alike. Our SLM-based, femur-
shaped implants possessed mechanical properties within 
the physiological range of the host bone, while its fully 
interconnected porous structure is considered to be within 
the range required for osteoconduction (Table 1) (Van der 
Stok et al., 2013a). Furthermore, the fatigue properties of 
the porous implants indicate that the biomechanical support 
is temporary (Amin Yavari et al., 2013). The implants were 
therefore capable of offering sufficient mechanical support 
in vivo, while stimulating bone regeneration through 
osteoconduction in the segmental bone defects (Van der 
Stok et al., 2013a; Van der Stok et al., 2013b).
 In addition to mechanical support, biomaterials should 
also offer a surface that facilities osseointegration, i.e. 
intimate apposition of bone matrix onto the implant surface 
(Puleo and Nanci, 1999). The bone-implant interface of 
most metallic biomaterials including titanium usually 
consists of an interfacial fibrous-like layer (also called 
Fig. 8. Direct comparison between BMP-2 release 
from fibrin and gelatin on bone regeneration. In the 
same in vivo model, using the same type of porous 
titanium implants and same batch of BMP-2, 
results from using HMW-BMP-Fb gels (this work) 
or gelatin nanosphere gels (Van der Stok et al., 
2013b) were compared. Using gelatin nanosphere 
gels loaded with 3 µg BMP-2 predominantly 
led to bone regeneration outside or inside the 
porous titanium implants (a1) without bridging 
the entire defect (b1). In contrast, HMW-BMP-
Fb gels (loaded with the same dose of BMP-2) 
led to complete bridging with restoration of the 
medullary canal (a2) and the cortex (b2). Bar 
indicates 1 mm.
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laminae limitantes) (Puleo and Nanci, 1999). The formation 
of this fibrous-like layer can be avoided by relatively 
simple treatments that have been shown to improve 
osseointegration of solid titanium implants (Wennerberg 
and Albrektsson, 2009). We optimised the treatment of 
the porous titanium implants used in this study (Amin 
Yavari et al., 2014b), to not only improve apatite formation 
and cellular attachment, but also cell proliferation and 
osteogenic differentiation of osteoprogenitor cells (Amin 
Yavari et al., 2014b).
 Bone graft substitutes should also be able to induce 
bone regeneration, which can be induced by a variety of 
bone morphogenetic proteins (BMPs), including BMP-2 
and BMP-7 (Groeneveld and Burger, 2000). BMP-2 is 
mainly released during the first few days of the natural 
bone regeneration process, and BMP-7 plays a more 
important role during the later phase (Gerstenfeld et al., 
2003). Both BMP-2 and BMP-7 received FDA-approval 
(Termaat et al., 2005), but their use in humans is currently 
heavily debated (Carragee et al., 2011). Although the 
osteoinductive effect of BMP-2 has been demonstrated 
in a wide variety of species (including rats, rabbits, dogs, 
sheep and non-human primates) (An and Friedman, 1999), 
it is often argued that one must be cautious in assuming 
that stromal cells from other species may serve as models 
for inducible osteogenesis in human marrow stromal cells 
(Diefenderfer et al., 2003). BMP-induced side effects, 
including cyst-like bone formation and soft tissue swelling, 
are likely caused by supra-physiological dosages used in 
humans (Carragee et al., 2011) and these adverse effects 
were recently reproduced in a similar in vivo model as 
used in this study with BMP-2 concentrations exceeding 
20 µg per defect (Angle et al., 2012; Zara et al., 2011). In 
contrast, a dose between 2.5 and 10 µg was found to be 
safe and effective for various other BMP release systems 
including alginate-based (Boerckel et al., 2011), poly-L-
lactic acid (PLLA)-based (Wei et al., 2007) or silk-based 
(Bessa et al., 2010) scaffolds. Based on these results we 
used 3 µg BMP-2 per implant. Furthermore, Schmoekel 
et al. demonstrated that with less soluble nonglycosylated 
BMP-2, the required cytokine dose could even be further 
reduced (Schmoekel et al., 2004).
 Surface-treated porous titanium was loaded with BMP-
2 through incorporation in physiologically concentrated 
fibrin gels. This is different from fibrin gels that have been 
used in trauma and orthopaedic surgery as “fibrin glue”, 
as these sealants are made of highly supra-physiological 
fibrinogen concentrations (Janmey et al., 2009). This 
supra-physiological concentration (50-100 mg/L) ensures 
quick and effective clotting, and is therefore primarily used 
as a haemostatic agent. Supra-physiological fibrinogen 
concentrations were also used to deliver BMP-2 in several 
bone defect models (Chung et al., 2007; Kaipel et al., 2012; 
Kim et al., 2008; Koo et al., 2013; Koo et al., 2012; La et 
al., 2012; Schmoekel et al., 2004; Schmokel et al., 2004; 
Schutzenberger et al., 2012; Yang et al., 2010; Yang et 
al., 2012). Schützenberger et al. showed that fibrin gels 
outperformed the currently clinically used absorbable 
collagen sponges as BMP-release properties of fibrin, 
in contrast to those of collagen, allow to use 85 % less 
cytokine without compromising the regenerative success 
(Schutzenberger et al., 2012). However, the high fibrinogen 
concentration of these supra-physiologically concentrated 
fibrin glues have a limiting effect on cell mobility and 
ingrowth (Nürnberger et al., 2010; Peterbauer-Scherb 
et al., 2012). In vivo, fibrin constitutes only 0.25 % of 
the volume of a blood clot (Weisel, 2004), which was 
mimicked in the current study by preparing fibrin gels of 
physiological concentrations (2-4 mg/L). It is tempting to 
speculate that at these concentrations, fibrin fibres form a 
more open network that more effectively promoted cell 
migration and cell ingrowth (Seebach et al., 2014). This 
open network structure and fibrin fibre adherence was 
perfectly supported by the surface-treated porous titanium 
(Fig. 1c). This temporary fibrin network is not expected to 
remain intact in vivo for more than a few days (Schmokel et 
al., 2004), but the results obtained in this study suggest that 
this is sufficient to adequately induce bone regeneration. 
Our approach mimics physiological fracture healing, 
during which BMP-2 is entrapped in the spontaneously 
formed fracture haematoma to induce differentiation of 
mesenchymal stem cells into osteoblasts (Onishi et al., 
1998). These osteoblast subsequently start to produce more 
BMP-2 and other important osteogenic cytokines to reach 
a maximum activity after 4-7 days (Kirker-Head, 1995).
 Physiologically concentrated fibrin gels prepared 
from HMW fibrinogen were expected to improve bone 
regeneration, as compared to gels prepared from UNF 
fibrinogen, because HMW fibrinogen has been shown to 
promote angiogenesis in vitro and in vivo in our earlier 
studies (Kaijzel et al., 2006). UNF fibrin gels contain 
30 % low molecular weight fibrinogen and, compared 
to 100 % HMW fibrinogen, contamination with more 
than 10 % of LMW fibrinogen gradually decreased the 
formation of tube-like structure in vitro in a dose-depend 
manner (Kaijzel et al., 2006). However, implants with 
HMW-Fb gels alone did not enhance bone regeneration 
and performed similar to implants with UNF-Fb gels or 
empty porous titanium implants (Fig. 2 and 5). BMP-2 
release from the fibrin gel is apparently providing the only 
osteoinductive stimulus, while HMW-Fb may still improve 
cell migration and angiogenesis. Whether using HMW-Fb 
to release BMP-2 is better than using UNF-Fb cannot be 
answered here and is a limitation of our study. However, 
HMW-fibrin gels with BMP-2 clearly outperformed 
previously used gelatin-based nanosphere gels with BMP-2 
(Van der Stok et al., 2013b), indicating the type of BMP-
2 carrier is of crucial importance. Although gelatin gels 
were capable of a sustained release of BMP-2 (Wang et 
al., 2013), this resulted in bone regeneration that mainly 
occurred around and inside the porous titanium implants 
(Fig. 8, a1). In addition, bone regeneration in that study did 
not lead to bridging of the grafted defects within twelve 
weeks (Fig. 8, b1). The mechanical strength also reached 
up to only 50 % of the original strength in that study (Wang 
et al., 2013). In contrast, physiological fibrin gels with low 
doses of BMP-2 boosted bone regeneration in the present 
study and completely bridged the majority of the grafted 
defects within four weeks (Fig. 8, b2), filling up more than 
50 % of the porous volume of the titanium implants with 
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regenerated bone. Twelve weeks following the surgery, the 
grafted femora were already more than twice as strong as 
their original strength (i.e. control femora Fig. 6).
Conclusion
This study reports the development of a new biomaterial 
combination, capable of stimulating complete bone 
regeneration in load-bearing segmental defects in rat 
femora. This optimal combination enabled quick bone 
regeneration within four weeks and full restoration of 
the original bone functionality and anatomical shape in 
this pre-clinical model. Since all used methods have been 
used separately in trauma and orthopaedic surgery, this 
combination should be evaluated in a large animal model or 
a clinical trial and this might result in an efficient bone graft 
substitute to graft load-bearing segmental bone defects in 
trauma and orthopaedic surgery.
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Discussion with Reviewers
Reviewer I: How can such an implant be fixed? In addition, 
can the fixation be integral part of the construct?
Authors: This is an intriguing question and obviously an 
important aspect of implant development. Because porous 
titanium implants are developed using selective laser 
melting (an additive manufacturing technique) options for 
screw or pin fixation can be completely integrated into the 
implant design. Examples of porous implants designs are 
more thoroughly described by Murr (Murr et al, 2010).
Reviewer II: When you look more than 12 weeks, may 
it be possible that the titanium mesh is impairing further 
bone formation as it is not degrading?
Authors: Bone formation would be impaired if 
implantation of the porous titanium implants result in a 
significant mechanical mismatch with the surrounding 
bone. This could cause stress shielding and subsequent 
bone resorption. However, extensive mechanical testing of 
the produced porous titanium indicated that due to fatigue 
the implants will lose some of their initial strength over 
time (Amin Yavari et al., 2013). This gradual weakening of 
the implants will avoid stress-shielding and is more likely 
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to stimulate bone formation rather than impairing bone 
formation. The main disadvantage of the fact that titanium 
implants do not degrade is the long-term risk of infection.
Reviewer III: Is this laboriously produced fibrin much 
better than commercially available material?
Authors: That may depend on the application. We have 
already shown that HMW-Fb stimulates angiogenesis in 
vitro (Kaijzel et al, 2006). As our commercial UNF-Fb does 
not behave much differently from HMW-Fb, with respect 
to bone bridging, we cannot clearly answer this for the 
present study. However, our novel combination of a fibrin 
gel within a highly porous titanium implant results in very 
good bone regeneration – at least when using HMW-Fb 
with low doses of BMP-2. The limitations of this study are 
now thoroughly addressed.
